SN-38

Because with SG, of course, you have more neutropenia and diarrhea.

at higher grade when you're a homozygote for the metabolic pathway for SN38, the payload for SG.

I think we really can think about this, patients who get a lot of aphthous ulcers, maybe not the best candidates again for DADO-DXT or patients who have underlying corneal issues.

We're learning a lot about managing all of these side effects as we go along.

There are a number of TROP2 ADCs in development and some that are clinically validated.

These include sasituzumab govotecan with a payload of SN38, datapodumab duroxtecan with a DXD payload, and emerging ADCs including sasituzumab terimotecan with a belotecan derivative.

We'll be going over some of the clinical data to support these in the next section.

In this next section, we'll review the efficacy data for TROP2-directed ADC in lung cancer, breast cancer, and other cancers.